SEC Comment Letter 0000000000-26-003517 to Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc.
Date: April 8, 2026 · CIK: 0001754068 · Accession: 0000000000-26-003517
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294883
Letter
Re: Kalaris Therapeutics, Inc. Registration Statement on Form S-3 Filed April 3, 2026 File No. 333-294883 Dear Andrew Oxtoby:
April 8, 2026
Andrew Oxtoby President and Chief Executive Officer Kalaris Therapeutics, Inc. 400 Connell Drive, Suite 5500 Berkeley Heights, New Jersey 07922
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Scott N. Lunin
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 8, 2026 Andrew Oxtoby President and Chief Executive Officer Kalaris Therapeutics, Inc. 400 Connell Drive, Suite 5500 Berkeley Heights, New Jersey 07922 Re: Kalaris Therapeutics, Inc. Registration Statement on Form S-3 Filed April 3, 2026 File No. 333-294883 Dear Andrew Oxtoby: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Scott N. Lunin </TEXT> </DOCUMENT>